SNY
Sanofi · Healthcare
47.60
0.61%(-0.29)
Prev. Close47.66
0.13%(+0.06)
Pre-marketLast Updated: — ET
52W L: $43.3252W H: $55.73
$47.38
CHG+3.98 (+9.17%)
H$48.35
L$43.26
VOL61M
SNY (1h)
Sanofi · Healthcare
Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig's potential as a respiratory treatment The exploratory VELVET phase 2b study did not meet its primary endpoint in moderate-to-severe atopic dermatitis In all studies, lunsekimig was well tolerated Paris, April 7, 2026. Phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints compared to placebo.
Aberdeen Group plc lifted its stake in shares of Sanofi (NASDAQ: SNY) by 22.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 467,241 shares of the company's stock after acquiring an additional 86,314 shares during the quarter. Aberdeen Group plc's
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Euro Pacific Asset Management LLC acquired a new stake in shares of Sanofi (NASDAQ: SNY) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 43,688 shares of the company's stock, valued at approximately $2,111,000. Other large investors also recently bought
Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg.
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
No recent filings